GlassScriptPhysician profile
Laura Sm Chang
NPI 1821225467
$5,398.17
in general payments reported to CMS, 2019-2025
25 companies · $1,662 in 2025
The $1,662 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $122 · 2022: $61.09 · 2023: $1,714 · 2024: $1,840 · 2025: $1,662.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,065 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,065.23 |
| Education | $149.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,430.94 | 2023-2025 | |
| Abbvie INC. | $946.23 | 2023-2025 | Skyrizi, Rinvoq |
| Regeneron Healthcare Solutions, INC. | $562.92 | 2022-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $422.46 | 2023-2025 | Ilumya, Winlevi |
| Incyte Corporation | $343.76 | 2023-2025 | Opzelura |
| Galderma Laboratories, L.P. | $196.51 | 2024-2025 | Nemluvio, Aklief |
| Amgen INC. | $167.03 | 2022-2025 | Otezla |
| Leo Pharma INC. | $162.32 | 2024-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $126.04 | 2024-2025 | Taltz, Ebglyss |
| Ucb, INC. | $121.94 | 2023-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $121.87 | 2020 | |
| Arcutis Biotherapeutics, INC. | $121.14 | 2023-2025 | Zoryve |
| Dermavant Sciences, INC. | $117.81 | 2023-2024 | Vtama |
| Mayne Pharma Commercial LLC | $90.23 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $75.92 | 2024-2025 | Sotyktu |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $70.03 | 2023-2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.38 | 2024-2025 | Spevigo |
| Journey Medical Corporation | $54.78 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.48 | 2023-2024 | Siliq, Duobrii |
| Botanix Sb INC | $37.17 | 2025 | Sofdra |
| Pfizer INC. | $33.72 | 2023 | |
| Genentech USA, INC. | $30.00 | 2023 | Venclexta |
| Mimedx Group, INC. | $25.56 | 2025 | |
| Almirall LLC | $20.70 | 2023 | Klisyri |
| Strata Skin Sciences, INC. | $19.23 | 2023 | Xtrac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.